title: Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin.
abstract: We assessed peripheral and liver CXCL10 levels in 15 patients treated with telaprevir/pegylated interferon/ribavirin. Induction of peripheral CXCL10 messenger RNA (mRNA) peaked (mean fold-induction [±SD], 3.1 ± 1.9) between treatment hour 6 and day 2, while induction of intrahepatic CXCL10 mRNA peaked (mean fold-induction [±SD], 1.3 ± 0.54) at hour 10 or day 4. Peripheral CXCL10 levels were higher at treatment hour 10 (P = .032) and day 2 (P = .009) in patients with undetectable virus 2 weeks after treatment initiation. Treatment hour 10 (P = .023) and peak (P = .034) intrahepatic CXCL10 levels were also higher in these patients. CXCL10 did not distinguish treatment responders from nonresponders. In conclusion, CXCL10 identified very rapid virological response in patients treated with a direct-acting antiviral.
  
  
  BACKGROUND
  NCT00892697.
authors.affiliation: Division of Gastroenterology and Hepatology, Weill Cornell Medical College.
authors.forename: Marija
authors.initials: M
authors.lastname: Zeremski
authors.affiliation: Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine Department of Biostatistics, State University of New York at Buffalo, New York.
authors.forename: Rositsa B
authors.initials: RB
authors.lastname: Dimova
authors.affiliation: Division of Gastroenterology and Hepatology, Weill Cornell Medical College.
authors.forename: Samantha
authors.initials: S
authors.lastname: Benjamin
authors.affiliation: Vertex Pharmaceuticals, Boston, Massachusetts.
authors.forename: Marina S
authors.initials: MS
authors.lastname: Penney
authors.affiliation: Vertex Pharmaceuticals, Boston, Massachusetts.
authors.forename: Martyn C
authors.initials: MC
authors.lastname: Botfield
authors.affiliation: Division of Gastroenterology and Hepatology, Weill Cornell Medical College Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine.
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Talal
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D054357:Chemokine CXCL10 / Q000032:analysis / Q000097:blood* / Q000235:genetics / Q000378:metabolism*; D005260:Female; D016174:Hepacivirus / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology*; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology / Q000627:therapeutic use*; D008099:Liver / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000494:pharmacology / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000494:pharmacology / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012254:Ribavirin / Q000494:pharmacology / Q000627:therapeutic use*; D019562:Viral Load / Q000187:drug effects; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; C114753:CXCL10 protein, human; D054357:Chemokine CXCL10; D016898:Interferon-alpha; D009842:Oligopeptides; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C486464:telaprevir; C100416:peginterferon alfa-2a
keywords: CXCL10; HCV; chemokines; liver inflammation